• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • BTK inhibitor
Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial
Posted inClinical Updates Medical News

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

Posted by By MedXY 08/02/2025
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
Read More
Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial
Posted inClinical Updates Wellness & Lifestyle

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

Posted by By MedXY 08/01/2025
Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.
Read More
  • Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet
  • Unlocking Precision Nutrition: Genetic Insights from the MIND Diet Trial for Cognitive Health
  • Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study
  • Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity
  • Decoding Metabolic Adaptation: Caloric Restriction’s Impact on Organ Size in the CALERIE 2 Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top